Key Points
- Insider Donald Dwyer bought 20,000 Vivani Medical shares for $19,600 at $0.98 each, increasing his stake by 36.36% to 75,000 shares.
- Vivani reported a quarterly loss of $0.08 per share, slightly better than analysts’ expected loss of $0.09.
- Analyst views are mixed: MarketBeat’s consensus rating is Hold, with a $3.75 average price target, while recent ratings include Buy and Sell recommendations.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) insider Donald Dwyer acquired 20,000 shares of the business's stock in a transaction that occurred on Thursday, November 12th. The shares were purchased at an average price of $0.98 per share, with a total value of $19,600.00. Following the completion of the transaction, the insider owned 75,000 shares of the company's stock, valued at $73,500. The trade was a 36.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Vivani Medical Trading Up 2.7%
VANI stock traded up $0.03 during trading on Friday, reaching $1.01. 368,707 shares of the stock were exchanged, compared to its average volume of 256,490. The business has a 50 day moving average price of $1.18 and a 200-day moving average price of $1.24. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66. The firm has a market capitalization of $91.10 million, a price-to-earnings ratio of -3.16 and a beta of 2.51.
Vivani Medical (NASDAQ:VANI - Get Free Report) last posted its quarterly earnings results on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on VANI shares. Wall Street Zen cut Vivani Medical from a "hold" rating to a "sell" rating in a report on Sunday. Weiss Ratings reissued a "sell (d-)" rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $3.75.
View Our Latest Stock Report on VANI
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
